Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bioalliance Pharma SA announces approval to start ReLive Phase III clinical trial in primary liver cancer in the U.S. and Germany


Wednesday, 4 Dec 2013 01:42pm EST 

Bioalliance Pharma SA:Says it has received authorization to start its Phase III ReLive clinical trial in primary liver cancer in the U.S. (IND approval), following the review of the Livatag development program by the FDA, as well as in Germany after the German health agency green light.Says it is also enlarging the study to Germany following the authorization granted by the BfArM (German health agency).